IgA Nephropathy Clinical Trials in Baltimore, Maryland
2 recruitingBaltimore, Maryland
Showing 1–2 of 2 trials
Recruiting
Phase 3
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
Primary IgA Nephropathy
Novartis Pharmaceuticals540 enrolled161 locationsNCT04557462
Recruiting
Phase 4
Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy
IgA Nephropathy
Calliditas Therapeutics AB60 enrolled38 locationsNCT06712407